EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Emerging Immunotherapy Options in HER‐2‐Positive Metastatic Breast Cancer: A Meta‐Analysis on Clinical Effectiveness and Safety of T‐DM1, Trastuzumab−Pertuzumab, and Trastuzumab Deruxtecan

Anulika Maris Omeaku, Anfal Anwar Sharif, Jameel Malhador Inal

European Journal of Cancer Care · 2026-01 · 2026 (1)

DOI: 10.1155/ecc/3726620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer Care, online erschienen am 11.03.2026. Verfasst von Anulika Maris Omeaku und 2 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HER‐2‐positive metastatic breast cancer (MBC) remains a clinical challenge due to its aggressive nature and resistance to conventional therapies. This meta‐analysis compares the clinical effectiveness and safety profiles of three key targeted immunotherapies: trastuzumab emtansine (T‐DM1), trastuzumab−pertuzumab, and trastuzumab deruxtecan, focusing on overall survival (OS), progression‐free survival (PFS), and adverse event profiles. Eligible studies were retrieved from PubMed and filtered for randomized controlled trials (RCTs) published between January 2019 and June 2024. Nonrandomized studies, reviews, and editorials were excluded. Data from four studies were included in the meta‐analysis, which was performed using RevMan software. The findings show that T‐DM1 presents a favorable balance between efficacy and safety, particularly in patients with prior trastuzumab‐based treatments. While trastuzumab deruxtecan demonstrated superior efficacy in heavily pretreated patients, it was associated with a higher risk of severe adverse events, particularly interstitial lung disease (ILD). Trastuzumab−pertuzumab remains the preferred first‐line treatment but shows reduced effectiveness in later treatment lines. Overall, while all three treatment regimens provide significant benefits for patients with HER‐2‐positive MBC, T‐DM1 emerges as a safer option for patients with cardiotoxicity risks. Trastuzumab−pertuzumab offers the best balance between efficacy and safety, while trastuzumab deruxtecan offers superior effectiveness in patients with advanced disease stages. These findings emphasize the importance of personalized treatment plans in optimizing clinical outcomes.

Zitieren

APA

Omeaku, A. M., Sharif, A. A., & Inal, J. M. (2026). Emerging Immunotherapy Options in HER‐2‐Positive Metastatic Breast Cancer: A Meta‐Analysis on Clinical Effectiveness and Safety of T‐DM1, Trastuzumab−Pertuzumab, and Trastuzumab Deruxtecan. European Journal of Cancer Care, 2026(1). https://doi.org/10.1155/ecc/3726620

Vancouver

Omeaku AM, Sharif AA, Inal JM. Emerging Immunotherapy Options in HER‐2‐Positive Metastatic Breast Cancer: A Meta‐Analysis on Clinical Effectiveness and Safety of T‐DM1, Trastuzumab−Pertuzumab, and Trastuzumab Deruxtecan. European Journal of Cancer Care. 2026;2026(1). doi:10.1155/ecc/3726620

BibTeX
@article{Omeaku2026,
  author = {Omeaku, Anulika Maris and Sharif, Anfal Anwar and Inal, Jameel Malhador},
  title = {Emerging Immunotherapy Options in HER‐2‐Positive Metastatic Breast Cancer: A Meta‐Analysis on Clinical Effectiveness and Safety of T‐DM1, Trastuzumab−Pertuzumab, and Trastuzumab Deruxtecan},
  journal = {European Journal of Cancer Care},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ecc/3726620}
}
Kostenlos starten →